Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes

The cornerstone of acute coronary syndrome therapy was firmly laid when ISIS-2 showed a 23% reduction in vascular death with aspirin versus placebo.1 The antithombotic effect of aspirin is largely explained by inhibition of COX 1, a central enzyme mediating platelet activation. This and pleotropic cardioprotective properties should be considered before forsaking or replacing aspirin, particularly early in the highly prothrombotic state of a new acute coronary syndrome (panel).2,3 The enhanced antithrombotic effect of combining aspirin with clopidogrel, an inhibitor of the P2Y12 receptor, another key pathway of platelet activation, revolutionised treatment of acute coronary syndromes.

email